Pacira BioSciences, Inc.

For the period ended Jun 30, 2026. Filed Aug 4, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 4, 2026

PCRX$36.46+0.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

	June 30,2026	December 31,2025
ASSETS
Current assets:
Cash and cash equivalents	$205,875	$158,545
Short-term available-for-sale investments	45,156	79,879
Accounts receivable, net	132,420	124,069
Inventories, net	134,575	152,863
Assets held for sale	67,337	—
Prepaid expenses and other current assets	29,852	32,618
Total current assets	615,215	547,974
Fixed assets, net	130,277	140,690
Right-of-use assets, net	44,920	41,777
Goodwill	19,642	20,214
Intangible assets, net	285,484	368,100
Deferred tax assets	124,598	123,854
Investments and other assets	23,842	22,308
Total assets	$1,243,978	$1,264,917
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$17,509	$15,150
Accrued expenses	93,499	95,601
Lease liabilities	10,298	9,839
Liabilities held for sale	705	—
Total current liabilities	122,011	120,590
Long-term debt, net	363,124	372,189
Lease liabilities	38,695	36,176
Contingent consideration	17,452	18,066
Deferred tax liabilities	4,070	4,213
Other liabilities	26,650	20,572
Total liabilities	572,002	571,806
Commitments and contingencies (Note 17)
Stockholders’ equity:
Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding at June 30, 2026 and December 31, 2025	—	—
Common stock, par value $0.001; 250,000,000 shares authorized; 48,840,889 shares issued and 39,822,298 shares outstanding at June 30, 2026 and 47,890,777 shares issued and 41,116,739 shares outstanding at December 31, 2025	49	48
Treasury stock, at cost, inclusive of excise tax and broker fees, 9,018,591 and 6,774,038 shares at June 30, 2026 and December 31, 2025, respectively	(227,013)	(176,565)
Additional paid-in capital	1,087,452	1,064,623
Accumulated deficit	(191,753)	(199,322)
Accumulated other comprehensive income	3,241	4,327
Total stockholders’ equity	671,976	693,111
Total liabilities and stockholders’ equity	$1,243,978	$1,264,917

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.